Skip to main content

Promoting your publication

Individual articles are widely promoted by our marketing and communications teams in a variety of ways. This could be through email updates, table of contents, email alerts, postings on the BioMed Central homepage, social media, blogs and/or press releases. These may result in higher levels of views and downloads for each article.

BioMed Central journals are also promoted at many major scientific conferences, to bring your work to the attention of professionals in your field.

In addition, all research published is automatically deposited in major bibliographic databases including PubMed and over 40 other abstracting and indexing databases. All of our journals are also indexed within SpringerLink, the world's most comprehensive online collection of scientific, technological and medical journals, books and reference works.

We would encourage you to promote your article via your own email lists, social media, Listservs, distribution at conferences and any other innovative techniques you wish to adopt.

  • Editorial Board
  • Editorial Team
  • Call for EBMs
  • Call for papers
  • Sign up for article alerts and news from this journal
  • Manuscript editing services
  • Contact us
  • Announcements

    C19 Rapid Review initiative

    Genome Medicine has joined the C19 Rapid Review initiative, a cross-publisher collaboration to ensure that COVID-19 research is reviewed and published as quickly and openly as possible. Learn more here

    Submissions from medRxiv 

    Authors are now able to submit manuscripts to Genome Medicine directly from medRxiv without having to re-upload files.

    Portable peer review

    To reduce time spent on serial submissions and iterative reviewing, Genome Medicine offers to consider manuscripts on the basis of reviews received at other journals. We also support transfers of reviews obtained at Genome Medicine to other journals, including those outside of BMC and Springer Nature. Learn more from our peer review policy page.

    COVID-19 submissions

    In response to the current SARS-CoV-2 pandemic Genome Medicine editors will treat relevant submissions with high priority.

Annual Journal Metrics